These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36858163)

  • 1. Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles.
    Yan H; Lin G; Liu Z; Gu F; Zhang Y
    Acta Biomater; 2023 Apr; 161():213-225. PubMed ID: 36858163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
    Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
    Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
    Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
    ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
    Li WH; Su JY; Li YM
    Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
    Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
    Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
    Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
    J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects.
    Cho HI; Celis E
    Cancer Res; 2009 Dec; 69(23):9012-9. PubMed ID: 19903852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA.
    Carson CS; Becker KW; Garland KM; Pagendarm HM; Stone PT; Arora K; Wang-Bishop L; Baljon JJ; Cruz LD; Joyce S; Wilson JT
    J Control Release; 2022 May; 345():354-370. PubMed ID: 35301055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma.
    Ly LV; Sluijter M; van der Burg SH; Jager MJ; van Hall T
    J Immunol; 2013 Jan; 190(1):489-96. PubMed ID: 23203930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway.
    Wilson NS; Yang B; Morelli AB; Koernig S; Yang A; Loeser S; Airey D; Provan L; Hass P; Braley H; Couto S; Drane D; Boyle J; Belz GT; Ashkenazi A; Maraskovsky E
    Immunol Cell Biol; 2012 May; 90(5):540-52. PubMed ID: 21894173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.
    Sharma RK; Elpek KG; Yolcu ES; Schabowsky RH; Zhao H; Bandura-Morgan L; Shirwan H
    Cancer Res; 2009 May; 69(10):4319-26. PubMed ID: 19435920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
    Chen S; Lee LF; Fisher TS; Jessen B; Elliott M; Evering W; Logronio K; Tu GH; Tsaparikos K; Li X; Wang H; Ying C; Xiong M; VanArsdale T; Lin JC
    Cancer Immunol Res; 2015 Feb; 3(2):149-60. PubMed ID: 25387892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Archaeosome adjuvant overcomes tolerance to tumor-associated melanoma antigens inducing protective CD8 T cell responses.
    Krishnan L; Deschatelets L; Stark FC; Gurnani K; Sprott GD
    Clin Dev Immunol; 2010; 2010():578432. PubMed ID: 21318177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response.
    Liang R; Xie J; Li J; Wang K; Liu L; Gao Y; Hussain M; Shen G; Zhu J; Tao J
    Biomaterials; 2017 Dec; 149():41-50. PubMed ID: 28992509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
    Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
    Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies.
    Gray JC; French RR; James S; Al-Shamkhani A; Johnson PW; Glennie MJ
    Eur J Immunol; 2008 Sep; 38(9):2499-511. PubMed ID: 18792403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
    Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
    Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
    Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
    Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma.
    Sainz V; Moura LIF; Peres C; Matos AI; Viana AS; Wagner AM; Vela Ramirez JE; S Barata T; Gaspar M; Brocchini S; Zloh M; Peppas NA; Satchi-Fainaro R; F Florindo H
    Acta Biomater; 2018 Aug; 76():193-207. PubMed ID: 29940370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.